Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Richard Eek"'
Autor:
Warwick Benson, Tracey Gerber, Meaghan Wall, K. M. Taylor, Devendra K Hiwase, Piers Blombery, Richard Eek, Melita Kenealy, Diana Zannino, John F. Seymour, Marlyse A. Debrincat, Steve Jong, Mark P. Hertzberg, Daniela Zantomio, Will Stevenson, Ilona Cunningham
Publikováno v:
Haematologica
Standard treatment for higher risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast acute myeloid leukemia (AML) is azacitidine. In single arm studies, the addition of lenalidomide had been suggested to improve ou
Autor:
Wee Joo Chng, Bradley Augustson, Brian G.M. Durie, Jeffrey Sy. Huang, Hang Quach, Noemi Horvath, Yoon Sung Soo, Kim Ki-Hyun, Jae Hoon Lee, Jane Estell, Je-Jung Lee, Simon J. Harrison, Soo Mee Bang, Rajeev Rajagopal, Philip Campbell, Nichloas Murphy, Richard Eek, Belinda Butcher
Publikováno v:
Blood. 136:39-40
Background: The combination of carfilzomib with immunomodulatory drugs (IMiDs) and dexamethasone is active in multiple myeloma (MM). Carfilzomib, thalidomide, and dexamethasone (KTd) has been studied in upfront MM treatment but has not been studied i
Autor:
Bradley Augustson, Belinda Butcher, Wee Joo Chng, Tracey Gerber, Brian G.M. Durie, Nicholas E. Murphy, Richard Eek, Rajeev Rajagopal, Jane Estell, Slavisa Ninkovic, Simon J. Harrison, Hang Quach, Peter Mollee, Noemi Horvath, Philip Campbell, Robyn Hemme, Akash Kalro
Publikováno v:
Blood. 132:1955-1955
Background: Carfilzomib lenalidomide and dexamethasone (KRd) is FDA-approved for the treatment relapsed/refractory multiple myeloma (RRMM) based on data from the ASPIRE study (Stewart K et al. NEJM 2015). Thalidomide, a first generation immunomodulat